Medpace Logo

For Immediate Release: November 30, 2018

Julie Hopkins
513-579-9911 x 12627

Medpace Expands In-House Medical Expertise with the Addition of 3 New Physicians

CINCINNATI, OH — (November 30, 2018) — Medpace (MEDP) a scientifically-driven, global, full-service clinical contract research organization (CRO) known for its strong therapeutic and regulatory expertise, announced the addition of three physicians to its medical leadership team. Medpace’s unique, scientifically-driven approach to clinical research embeds medical expertise throughout trial design and execution, providing a high-science approach to clinical development. With the addition of these three highly-qualified physicians, Medpace can offer Sponsors even deeper expertise across a broad spectrum of diseases and technologies.

Richard S. Lee, MD

Dr. Richard S. Lee is a board-certified cardiothoracic surgeon with an extensive background in a full range of adult cardiac surgery, including valve repair and replacement, coronary artery bypass grafting, aortic aneurysm surgery, surgery for atrial fibrillation, and transcatheter aortic valve replacement.

Dr. Lee graduated summa cum laude from Yale University with a degree in Molecular Biophysics and Biochemistry. After graduating, he earned his medical degree, cum laude, from Harvard Medical School in Boston Massachusetts.  He completed a residency in general surgery at Massachusetts General Hospital as well as a residency in cardiothoracic surgery from Stanford University Medical Center in California. He has solid research experience in transplantation immunology.  Dr. Lee has been board certified in cardiothoracic surgery since 2007.

Yulia Lurye, MD

Dr. Yulia Lurye is a clinical research physician with board-certifications in endocrinology, pediatric endocrinology and nephrology. She brings over 10 years of clinical trial experience, including seven years as an investigator and six as a medical director working across all phases within a Clinical Research Organization (CRO). Her specialties include: metabolic disorders, cardio-vascular, infectious diseases, kidney/renal and liver diseases, transplantation & immunosuppressive therapy, rare diseases, and growth disorders.

Dr. Lurye received her medical degree from the Russian State Medical Academy where she graduated with the highest honors. She also holds certificates in liver transplantation, kidney and pancreas transplantation, transfusiology, GCP and obesity treatment.

David B Schneider, MD, MBA

Dr. David Schneider is an Internist with a broad background in pharmaceutical research. He has over 11 years of experience in clinical drug development, including three years as a PI. He has global expertise in the design and medical oversight of clinical trials in the areas of Metabolic, Cardiology and Neurology.

Dr. Schneider graduated magna cum Laude from the University of Kentucky with a Biology degree. After graduation, he stayed in Lexington and earned his medical degree from the University of Kentucky College of Medicine. He earned his MBA from Xavier University in 2010.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,800 people across 36 countries.